Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 September 2023Website:
http://www.neumoratx.comNext earnings report:
30 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 27 Jun 2024 20:01:34 GMTDividend
Analysts recommendations
Institutional Ownership
NMRA Latest News
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response
The FDA has halted Neumora's phase I study of NMRA-266 for certain neuropsychiatric disorders, causing a drop in the company's stock price.
The stock of Neumora Therapeutics is dropping on Monday following the company's announcement of a clinical hold on a Phase 1 trial for NMRA-266, with the FDA responsible for this decision.
Neumora Therapeutics (NMRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November:
Neumora focuses on central nervous system disorders. Its lead therapy is Navacaprant to treat MDD.
What type of business is Neumora Therapeutics Common Stock?
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
What sector is Neumora Therapeutics Common Stock in?
Neumora Therapeutics Common Stock is in the Healthcare sector
What industry is Neumora Therapeutics Common Stock in?
Neumora Therapeutics Common Stock is in the Biotechnology industry
What country is Neumora Therapeutics Common Stock from?
Neumora Therapeutics Common Stock is headquartered in United States
When did Neumora Therapeutics Common Stock go public?
Neumora Therapeutics Common Stock initial public offering (IPO) was on 15 September 2023
What is Neumora Therapeutics Common Stock website?
https://www.neumoratx.com
Is Neumora Therapeutics Common Stock in the S&P 500?
No, Neumora Therapeutics Common Stock is not included in the S&P 500 index
Is Neumora Therapeutics Common Stock in the NASDAQ 100?
No, Neumora Therapeutics Common Stock is not included in the NASDAQ 100 index
Is Neumora Therapeutics Common Stock in the Dow Jones?
No, Neumora Therapeutics Common Stock is not included in the Dow Jones index
When does Neumora Therapeutics Common Stock report earnings?
The next expected earnings date for Neumora Therapeutics Common Stock is 30 August 2024